Real-World Adherence and Persistence to Glucagon-Like Peptide-1 Receptor Agonists Among Non-Diabetic Obese Commercially Insured Adults Authors: A.M. Wilson, PharmD; B.D. Hunter, MS; K....

Proposed indications Hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS). FDA approval timeline April 6, 2026...

Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Durvalumab (Imfinzi) AstraZeneca; MedImmune IV Programmed...

CNN: At 37:03, listen to fitness expert Jillian Michaels cite Prime/Magellan Rx research on a podcast recording of a June 21 CNN broadcast

Jan. 28, 2025 – hydrochlorothiazide (Inzirqo) 505(b)(2) NDA approval; Standard Review; first oral suspension formulation of hydrochlorothiazide; previously available oral solutions are no longer...

Proposed indications Non-muscle invasive bladder cancer (NMIBC) FDA approval timeline March to May 2026 Standard Review Place in therapy Sasanlimab is a humanized immunoglobulin G4 (IgG4)...

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care Click on the poster image to view the full-size version. Validation of Long-term Savings from a...

Read more about Prime’s leading research and insights Real-World 2-Year Clinical Outcomes Following Initiation of Glucagon-Like Peptide-1 Agonists to Treat Obesity Without Diabetes Among a...

publications High-Cost Therapy Profile: April 2025 Deramiocel Intravenous (IV) | Nippon Shinyaku Co., Ltd./Capricor Therapeutics, Inc. Clinical deep dive Disease state overview DMD is a severe,...

PUBLICATIONS FDA Decisions Expected: February 2025 Drug pipeline for February 2025 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

Kresladi, by Rocket Pharmaceuticals, is undergoing it’s second review by the FDA for the treatment of severe leukocyte adhesion deficiency type 1 (LAD-1). In June 2024, the FDA issued a CRL for...

May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents and children. This Clinical Insights white paper...

May 15, 2025 Oncology-Gene therapy Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Bifikafusp Alfa; Onfekafusp...

January 31, 2025 All brand names are property of their respective owners. Dec. 13, 2024 – cosibelimab-ipdl (Unloxcyt) Checkpoint’s Unloxcyt has received FDA approval for the treatment of adults...

Abbvie is seeking Accelerated Approval of Teliso-V in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell...

cover image for Reimagine Cancer Care: Insights That Drive Smarter Decisions Explore the latest oncology trends, payer strategies and pipeline updates shaping the future of managed care. Prime...

According to an analysis led by US-based Prime Therapeutics and published in the Journal of Managed Care & Specialty Pharmacy in August, on average only one-third of people continue taking GLP-1...

cover image for summer 2025 New therapies, payer strategies and pipeline updates shaping the future of managed care  Prime Therapeutics /summer-2025-prime-therapeutics-report The Prime Therapeutics...

Nov. 29, 2024 - ustekinumab-kfce (Yesintek) The FDA has approved Biocon’s Yesintek as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is indicated for all...

From research posters and education sessions to the Pharmacy Friends podcast, Prime has you covered on the latest managed care pharmacy insights

Real-World 3-Year Cost Impact Assessment of Glucagon-Like Peptide-1 Agonists to Treat Obesity Among Commercially Insured Members without Diabetes This study earned a silver award from AMCP. It...

2M HighTouchRx® has contributed to more than $200 million in savings across commercial and Medicare plans since 2022. Prime serves approximately 6 million Floridians. IntegratedRx® connects...

The Spring 2026 Prime Therapeutics Report delivers a forward-looking view of specialty and rare disease management—highlighting breakthrough approvals, expanding pipelines and the payer strategies...

A roundup of Prime's award-winning presentations and insights at AMCP Nexus in Las Vegas.

Evaluating Case Management Referral Patterns: Insights From an Enhanced Utilization anagement Program Real-World Patterns of On-Demand Therapy Utilization Following Initiation of Long-Term...

Reimagine your pharmacy benefit partner Get expert insights Go Somewhere Save, Simplify, Support™ Biologic drugs are transforming lives for the better, yet often at a substantial cost. Biosimilars,...

Care Specialists program Help your members on high-cost clinical drugs Insert Link Help members and their prescribers make better decisions about medicines through this clinical intelligence hub...

research 10 research posters presented by Prime at AMCP Nexus 2024 Studies include Prime’s GLP-1 obesity research, health equity, and real world case studies Evaluating the 10-Year Impact of an...

*select countries included adolescents 12 years and older weighing 30 kg or more Autoimmune/immunology Proposed indications Treatment of Steroid-Refractory Acute Graft vs. Host Disease (SR-aGVHD) –...

More than 300 pharma representatives attended this annual gathering to learn more about what Prime/MRx has to offer

Oncology Insights Oncology Case Management and Navigation: How do they differ? Caring for and treating a patient with cancer is complex. Many patients struggle to coordinate therapy, manage...

Academy of Managed Care Pharmacy (AMCP)'s Annual Meeting gathers thousands of health plan, pharmacy benefit management and biopharmaceutical experts to help define the future of managed care pharmacy.

Weight loss Support and empower weight loss in a healthy, manageable and sustainable way with customized paths for each member. Medication management Improve drug adherence or reduce the number of...

50M Footnotes As many as 50M people in the United States have an autoimmune disease, making it the third most prevalent disease category, surpassed only by cancer and heart disease.2 Unlock...

Flexible, cost-effective, strategic partnership Specialty drugs have changed the pharmacy landscape over the past decade and now represent more than half of total drug spend. Having a strong...

13th annual report the preeminent source for medical benefit drug trend

Magellan's Michelle Booth and Andy Killpack presented today at the annual AMCP meeting in San Antonio to discuss equitable access to recombinant adeno-associated virus (rAAV) gene therapy as there...

High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...

May 22, 2025 – mepolizumab (Nucala) GlaxoSmithKline; an IL-5 antagonist monoclonal antibody New indication: add-on maintenance treatment of adults with inadequately controlled chronic obstructive...

Insert Link Medical Formulary Strategy ensures the most appropriate and clinically effective medical benefit drugs are evaluated with product-preferencing strategies, for all lines of business....

Medication Nonadherence Social Determinants of Health Risk Score: Development and Use 2024 AMCP Annual Posters Real-World First Year Cost-Effectiveness Assessment of Glucagon-Like Peptide-1...

Cover image Specialty insights to watch Prime Therapeutics /summer-2026-prime-therapeutics-report The Summer 2026 Prime Therapeutics Report delivers practical insights on the therapies, trends and...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Clinical deep dive Disease state overview WAS is a rare, X-linked, genetic disorder characterized by thrombocytopenia, eczema, immunodeficiency, and increased risk of autoimmunity and...

All brand names are property of their respective owners. References Kim SY, Park HS, Chiang AC. Small Cell Lung Cancer: A Review. JAMA. 2025;333(21):1906-1917. doi:10.1001/jama.2025.0560...

Last year, Oncology Insights brought you the most talked about topics in 2024. As we enter this new year, let us review these impactful and potentially practicing changing subjects that are likely...

Methodological Framework for Propensity Adjusted Benchmarks for Pharmacy Key Performance Indicators The purpose of the study was to create a methodological framework for using propensity score...

Clinical deep dive Disease state overview Myelodysplastic syndromes (MDS) are classified as disorders in which there are abnormal (dysplastic) hematopoietic stem cells in the bone marrow, leading...

Whitepaper Tab 1 Myth 1 Myth 2 Myth 3 Myth 4 Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed nec ornare mi. Praesent ultrices ipsum eget est rutrum, eget congue orci molestie. Sed diam...

For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

Clinical deep dive Disease state overview MacTel type 2 is a rare neurodegenerative disease that affects the macula, which processes central and color vision. It is a bilateral asymmetric...

Empowering client, providers and members Building a trusted, transparent PBM Tab 1 2021 – Current 2015 – 2020 2010 – 2014 1998 – 2009 Helping improve care, reducing cost through integration See our...

Publications High Cost Therapy Profile: October 2024 Eladocagene Exuparvovec October 15, 2024 References PTC Therapeutics announces FDA acceptance and Priority Review of the BLA for UpstazaTM. PTC...

Prime is pleased to present the seventh edition of the Employer Market Insights Report. Within this one-of-a-kind publication, you’ll find critical pharmacy trend insights that will help you make...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Marquee event showcased new Prime, our energy, ambition and transformative journey

Eyebrow High-Cost Therapy Profile: August 2024 Detailed information about intravenous (IV) linvoseltamab Oncology Linvoseltamab, intravenous (IV) Regeneron Pharmaceuticals Proposed indications...

Home Our solutions Modern technology MyRxInsights Our advanced analytics platform helps boost your clinical impact and drive down costs by delivering descriptive, diagnostic, predictive and...

When you fill your specialty prescription, we automatically enroll you in our Care Specialists program. Our care specialists are pharmacists and nurses who are specially trained in your condition....

Research awards AMCP Silver Award – Controlled Substances Triple Threat Overlapping Days: Relationship with Healthcare Utilization and Costs Academy of Managed Care Pharmacy: Annual Meeting AMCP...